Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41577-021-00553-8 http://scihub22266oqcxt.onion/10.1038/s41577-021-00553-8 33850327!8043092!33850327     free     free     free       Nat+Rev+Immunol 2021 ; 21 (6): 337-339 Nephropedia Template TP {{tp|p=33850327|t=2021. Is IL-6 a key cytokine target for therapy in COVID-19?|pdf=|usr=}}{{33850327}} gab.com Text Is IL-6 a key cytokine target for therapy in COVID-19 JO: Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33850327 #FOAvip The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here. Twit Text FOAVip Is IL-6 a key cytokine target for therapy in COVID-19 ????Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33850327 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33850327 #FOAvip English Wikipedia <ref>{{Cite pmid|33850327}}</ref> Is IL-6 a key cytokine target for therapy in COVID-19? #MMPMID33850327 Jones SA; Hunter CA Nat Rev Immunol 2021[Jun]; 21 (6): 337-339 PMID33850327show ga The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use[MESH] |COVID-19/complications/*immunology[MESH] |Cytokine Release Syndrome/*drug therapy/etiology/*immunology[MESH] |Cytokines/antagonists & inhibitors[MESH] |Humans[MESH] |Interleukin-6/*antagonists & inhibitors/blood[MESH] |Receptors, Interleukin-6/antagonists & inhibitors[MESH] |Severity of Illness Index[MESH]Is IL-6 a key cytokine target for therapy in COVID-19?(epmc).pdf DeepDyve Pubget Overpricing